Amylin gets full value from $7bn BMS/AZ acquisition

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.